AI Article Synopsis
- The study looked at how two types of diabetes medicines, SGLT2I and DPP4I, affect the risk of prostate cancer in men with type-2 diabetes.
- Researchers found that men using SGLT2I had a lower chance of getting prostate cancer compared to those using DPP4I.
- This suggests that SGLT2I might be a safer option for men with type-2 diabetes when it comes to the risk of developing prostate cancer.
Article Abstract
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. This study aims to compare the risks of prostate cancer between SGLT2I and dipeptidyl peptidase-4 inhibitors (DPP4I) amongst T2DM patients.
Design, Setting And Participants: This was a retrospective population-based cohort study of prospectively recorded data on male patients with T2DM who were prescribed either SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 from Hong Kong.
Methods: The primary outcome was new-onset prostate cancer. The secondary outcomes included cancer-related mortality and all-cause mortality. Propensity score matching (1:1 ratio) using the nearest neighbor search was performed and multivariable Cox regression was applied. A three-arm analysis including the glucagon-like peptide-1 receptor agonist (GLP1a) cohort was conducted.
Results: This study included 42129 male T2DM patients (median age: 61.0 years old [SD: 12.2]; SGLT2I: n = 17,120; DPP4I: n = 25,009). In the propensity score matched cohort, the number of prostate cancers was significantly lower in SGLT2I users (n = 60) than in DPP4I (n = 102). Over a follow-up duration of 5.61 years, SGLT2I was associated with lower prostate cancer risks (HR: 0.45; 95% CI: 0.30-0.70) than DPP4I after adjustments. The subgroup analyses showed that the interactions between SGLT2I and age, hypertension, heart failure, and GLP-1a were not statistically significant. The result remained consistent in the sensitivity analysis.
Conclusion: The study demonstrated SGLT2I was associated with lower risks of new-onset prostate cancer after propensity score matching and adjustments compared to DPP4I amongst T2DM patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diabet.2024.101571 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.
Histopathology
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Aims: Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes.
View Article and Find Full Text PDFCancer in Orthopaedic Surgeons: Results of an American Academy of Orthopaedic Surgeons (AAOS) Survey.
Iowa Orthop J
January 2025
Department of Orthopaedics, University of Rochester Medical Center, Rochester, New York, USA.
Background: There is a currently limited data regarding cancer risk in Orthopaedic Surgeons. This study summarizes a survey on cancer prevalence in orthopaedic surgeons.
Methods: A cancer prevalence survey was emailed to all 23,370 members of the American Academy of Orthopaedic Surgeons (AAOS).
Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer.
Eur Urol Open Sci
January 2025
Department of Radiation Medicine and Applied Sciences, University of California San Diego School of Medicine, La Jolla, CA, USA.
Multiparametric magnetic resonance imaging (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, the major limitations are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to address these issues include use of biparametric magnetic resonance imaging (bpMRI) and advanced, quantitative magnetic resonance imaging (MRI) techniques.
View Article and Find Full Text PDFData-integration with pseudoweights and survey-calibration: application to developing US-representative lung cancer risk models for use in screening.
J R Stat Soc Ser A Stat Soc
January 2025
Division of Cancer Epidemiology & Genetics, National Cancer Institute, Biostatistics Branch, Rockville, USA.
Accurate cancer risk estimation is crucial to clinical decision-making, such as identifying high-risk people for screening. However, most existing cancer risk models incorporate data from epidemiologic studies, which usually cannot represent the target population. While population-based health surveys are ideal for making inference to the target population, they typically do not collect time-to-cancer incidence data.
View Article and Find Full Text PDFComorbidities And Reducing InEquitieS (CARES): Feasibility of self-monitoring and community health worker support in management of comorbidities among Black breast and prostate cancer patients.
Contemp Clin Trials Commun
February 2025
Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA.
Background: Black individuals with cancer have a higher prevalence of comorbidities and a worse cancer prognosis than other racial groups in the US. As part of a quality improvement project, we aimed to demonstrate feasibility of self-monitoring and community health worker (CHW) support among managing comorbidities for Black individuals with breast or prostate cancer.
Methods: In a single arm, pre-post study, we enrolled patients with diabetes and/or hypertension who identified as Black and were diagnosed with 1) stage 0-IV breast cancer, or 2) prostate cancer and on long-term androgen-deprivation therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!